Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.

Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K.

Am J Pathol. 2016 Jul;186(7):1900-1912. doi: 10.1016/j.ajpath.2016.02.024. Epub 2016 May 13.

2.

The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase.

Caruso JA, Akli S, Pageon L, Hunt KK, Keyomarsi K.

Oncogene. 2015 Jul;34(27):3556-67. doi: 10.1038/onc.2014.284. Epub 2014 Sep 8.

3.

Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.

Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK, Keyomarsi K.

Cancer Res. 2013 Sep 1;73(17):5556-68. doi: 10.1158/0008-5472.CAN-13-0013. Epub 2013 Aug 16.

4.

LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.

Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K.

PLoS Genet. 2012;8(3):e1002538. doi: 10.1371/journal.pgen.1002538. Epub 2012 Mar 29.

5.

Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer.

Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K.

Cell Cycle. 2012 Apr 1;11(7):1468-76. doi: 10.4161/cc.19882. Epub 2012 Apr 1.

6.

Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.

Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K.

Cancer Res. 2011 May 1;71(9):3377-86. doi: 10.1158/0008-5472.CAN-10-4086. Epub 2011 Mar 8.

7.

A novel interaction between HER2/neu and cyclin E in breast cancer.

Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK.

Oncogene. 2010 Jul 8;29(27):3896-907. doi: 10.1038/onc.2010.151. Epub 2010 May 10.

8.

Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.

Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K.

Clin Cancer Res. 2010 Feb 15;16(4):1179-90. doi: 10.1158/1078-0432.CCR-09-1787. Epub 2010 Feb 9.

9.

Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.

Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K.

Cancer Res. 2007 Aug 1;67(15):7212-22.

10.

Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer.

Barton MC, Akli S, Keyomarsi K.

J Cell Physiol. 2006 Dec;209(3):686-94. Review.

PMID:
17001684
11.

Low-molecular-weight cyclin E: the missing link between biology and clinical outcome.

Akli S, Keyomarsi K.

Breast Cancer Res. 2004;6(5):188-91. Epub 2004 Jul 7.

12.

Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.

Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K.

Cancer Res. 2004 May 1;64(9):3198-208.

13.

Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy.

Akli S, Keyomarsi K.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S38-47. Review.

PMID:
14508079
14.

The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells.

Wingate H, Bedrosian I, Akli S, Keyomarsi K.

Cell Cycle. 2003 Sep-Oct;2(5):461-6.

PMID:
12963845
15.

E1A can provoke G1 exit that is refractory to p21 and independent of activating cdk2.

Akli S, Zhan S, Abdellatif M, Schneider MD.

Circ Res. 1999 Aug 20;85(4):319-28.

PMID:
10455060
16.

Retrovirus-mediated enzymatic correction of Tay-Sachs defect in transduced and non-transduced cells.

Guidotti J, Akli S, Castelnau-Ptakhine L, Kahn A, Poenaru L.

Hum Mol Genet. 1998 May;7(5):831-8.

PMID:
9536087
17.

Phenotypic alteration of astrocytes induced by ciliary neurotrophic factor in the intact adult brain, As revealed by adenovirus-mediated gene transfer.

Lisovoski F, Akli S, Peltekian E, Vigne E, Haase G, Perricaudet M, Dreyfus PA, Kahn A, Peschanski M.

J Neurosci. 1997 Oct 1;17(19):7228-36.

18.

Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors.

Haase G, Kennel P, Pettmann B, Vigne E, Akli S, Revah F, Schmalbruch H, Kahn A.

Nat Med. 1997 Apr;3(4):429-36.

PMID:
9095177
19.

Restoration of hexosaminidase A activity in human Tay-Sachs fibroblasts via adenoviral vector-mediated gene transfer.

Akli S, Guidotti JE, Vigne E, Perricaudet M, Sandhoff K, Kahn A, Poenaru L.

Gene Ther. 1996 Sep;3(9):769-74.

PMID:
8875224
20.

[Gene therapy of neurological diseases].

Kahn A, Haase G, Akli S, Guidotti JE.

C R Seances Soc Biol Fil. 1996;190(1):9-11. French.

PMID:
8881264
21.

Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease.

Cohen-Tannoudji M, Marchand P, Akli S, Sheardown SA, Puech JP, Kress C, Gressens P, Nassogne MC, Beccari T, Muggleton-Harris AL, et al.

Mamm Genome. 1995 Dec;6(12):844-9.

PMID:
8747922
22.

Using adenoviral vectors to transfer the CNTF gene into the CNS.

Lisovoski F, Peltekian E, Akli S, Vigne E, Bouchard C, Haase G, Dreyfus P, Perricaudet M, Kahn A, Peschanski M.

Restor Neurol Neurosci. 1995 Jan 1;8(1):45-6. doi: 10.3233/RNN-1995-81211. No abstract available.

PMID:
21551805
23.

In vivo transfer of a marker gene to study motoneuronal development.

Lisovoski F, Cadusseau J, Akli S, Caillaud C, Vigne E, Poenaru L, Stratford-Perricaudet L, Pericaudet M, Kahn A, Peschanski M.

Neuroreport. 1994 May 9;5(9):1069-72.

PMID:
8080960
24.

Molecular epidemiology of Tay-Sachs disease in Europe.

Poenaru L, Akli S.

Biomed Pharmacother. 1994;48(8-9):341-6.

PMID:
7858168
25.

Adenoviral vector as a gene delivery system into cultured rat neuronal and glial cells.

Caillaud C, Akli S, Vigne E, Koulakoff A, Perricaudet M, Poenaru L, Kahn A, Berwald-Netter Y.

Eur J Neurosci. 1993 Oct 1;5(10):1287-91.

PMID:
8275231
26.

[Gene transfer with a therapeutic purpose in the central nervous system].

Peschanski M, Lisovoski F, Akli S, Caillaud C, Wahrman P, Weber-Benarous A, Vigne E, Stratford-Perricaudet L, Perricaudet M, Kahn A.

Nouv Rev Fr Hematol. 1993 Jun;35(3):299-300. French. No abstract available.

PMID:
8337147
27.

Transfer of a foreign gene into the brain using adenovirus vectors.

Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, Kahn A, Peschanski MR.

Nat Genet. 1993 Mar;3(3):224-8.

PMID:
8485577
28.

A null allele frequent in non-Jewish Tay-Sachs patients.

Akli S, Chelly J, Kahn A, Poenaru L.

Hum Genet. 1993 Feb;90(6):614-20.

PMID:
8444467
29.

Ten novel mutations in the HEXA gene in non-Jewish Tay-Sachs patients.

Akli S, Chomel JC, Lacorte JM, Bachner L, Kahn A, Poenaru L.

Hum Mol Genet. 1993 Jan;2(1):61-7. Erratum in: Hum Mol Genet 1993 Apr;2(4):496.

PMID:
8490625
30.

Collaborative study of the molecular epidemiology of Tay-Sachs disease in Europe.

Akli S, Boue J, Sandhoff K, Kleijer W, Vamos E, Young E, Gatti R, Di Natale P, Motte J, Vanier MT, et al.

Eur J Hum Genet. 1993;1(3):229-38.

PMID:
8044648
31.

Human beta-mannosidosis: a 3-year-old boy with speech impairment and emotional instability.

Poenaru L, Akli S, Rocchiccioli F, Eydoux P, Zamet P.

Clin Genet. 1992 Jun;41(6):331-4.

PMID:
1623631
32.

Illegitimate transcription. Application to the analysis of truncated transcripts of the dystrophin gene in nonmuscle cultured cells from Duchenne and Becker patients.

Chelly J, Gilgenkrantz H, Hugnot JP, Hamard G, Lambert M, Récan D, Akli S, Cometto M, Kahn A, Kaplan JC.

J Clin Invest. 1991 Oct;88(4):1161-6.

33.

Seven novel Tay-Sachs mutations detected by chemical mismatch cleavage of PCR-amplified cDNA fragments.

Akli S, Chelly J, Lacorte JM, Poenaru L, Kahn A.

Genomics. 1991 Sep;11(1):124-34.

PMID:
1837283
34.

A "G" to "A" mutation at position -1 of a 5' splice site in a late infantile form of Tay-Sachs disease.

Akli S, Chelly J, Mezard C, Gandy S, Kahn A, Poenaru L.

J Biol Chem. 1990 May 5;265(13):7324-30.

35.

Prenatal diagnosis of mucolipidosis type II on first-trimester amniotic fluid.

Poenaru L, Mezard C, Akli S, Oury JF, Dumez Y, Boue J.

Prenat Diagn. 1990 Apr;10(4):231-5.

PMID:
1973293
36.

Msp1 RFLP in the human hexosaminidase beta peptide (Hex B) gene.

Gandy S, Castelnau L, Akli S, Kahn A, Poenaru L.

Nucleic Acids Res. 1989 Aug 25;17(16):6761. No abstract available.

37.

First trimester prenatal diagnosis of metachromatic leukodystrophy on chorionic villi by 'immunoprecipitation-electrophoresis'.

Poenaru L, Castelnau L, Besançon AM, Nicolesco H, Akli S, Theophil D.

J Inherit Metab Dis. 1988;11(2):123-30.

PMID:
2902245

Supplemental Content

Support Center